Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
Version 2 2021-07-09, 16:17
Version 1 2021-07-07, 16:27
media
posted on 2021-07-09, 16:17 authored by Adis Rapid Journals on behalf of:, Liting Wang, Ye Peng, Xiaohui Zeng, Liubao Peng, Sini Li, Shuxia Qin, Xiaomin Wan, Chongqing Tan<p><strong>Article full
text</strong></p>
<p><br>
The above summary slide represents the opinions of
the <b>authors</b>. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite). </p>
<p>© The authors, CC-BY-NC <b>2021</b>.<b>
</b></p>
